サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1166110

狭心症治療の世界市場 - 成長、将来展望、競合分析（2022年～2030年）

Angina Pectoris Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 117 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
狭心症治療の世界市場 - 成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月10日
発行: Acute Market Reports
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の狭心症治療市場について調査し、市場動向、薬剤のパイプライン分析、セグメント分析、企業プロファイルなどの情報を提供しています。

目次

第1章 序文

  • レポートの説明
  • 市場セグメンテーション
  • 調査手法

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界の狭心症治療市場
  • 世界の狭心症治療市場：薬剤クラス別（2021年）
  • 世界の狭心症治療市場：地域別（2021年）
  • COVID-19の影響
  • 魅力的な投資提案：地域別（2021年）
  • 競合分析
    • 主要な狭心症治療市場ベンダーの市場ポジショニング
    • 狭心症治療市場ベンダーが採用する戦略
    • 主要な業界戦略

第3章 狭心症治療市場：ビジネスの見通しと市場力学

  • イントロダクション
  • 世界の狭心症治療市場金額（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因・抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
  • PESTEL分析

第4章 狭心症治療市場：薬剤クラス別（2020年～2030年）

  • 市場概要
  • 成長と収益分析：2021年対2030年
  • 市場セグメンテーション
    • 抗血小板薬
    • βアドレナリン遮断薬
    • カルシウムチャネル遮断薬
    • 短時間及び長時間作用型ニトログリセリン
    • アンジオテンシン変換酵素阻害剤
    • 抗虚血剤
    • パイプライン分析

第5章 北米の狭心症治療市場（2020年～2030年）

  • 市場概要
  • 狭心症治療市場：薬剤クラス別（2020年～2030年）
  • 狭心症治療市場：地域別（2020年～2030年）
    • 北米

第6章 英国・欧州連合の狭心症治療市場（2020年～2030年）

  • 市場概要
  • 狭心症治療市場：薬剤クラス別（2020年～2030年）
  • 狭心症治療市場：地域別（2020年～2030年）
    • 英国・欧州連合

第7章 アジア太平洋の狭心症治療市場（2020年～2030年）

  • 市場概要
  • 狭心症治療市場：薬剤クラス別（2020年～2030年）
  • 狭心症治療市場：地域別（2020年～2030年）
    • アジア太平洋

第8章 ラテンアメリカの狭心症治療市場（2020年～2030年）

  • 市場概要
  • 狭心症治療市場：薬剤クラス別（2020年～2030年）
  • 狭心症治療市場：地域別（2020年～2030年）
    • ラテンアメリカ

第9章 中東・アフリカの狭心症治療市場（2020年～2030年）

  • 市場概要
  • 狭心症治療市場：薬剤クラス別（2020年～2030年）
  • 狭心症治療市場：地域別（2020年～2030年）
    • 中東・アフリカ

第10章 企業プロファイル

  • Abbott Laboratories Inc.
  • Astra Zeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Forest Laboratories Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
図表

List of Tables

  • TABLE 1 Global Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 Global Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 3 Global Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
  • TABLE 4 North America Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 North America Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 6 North America Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
  • TABLE 7 UK and European Union Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 8 UK and European Union Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 9 UK and European Union Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
  • TABLE 10 Asia Pacific Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 11 Asia Pacific Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 12 Asia Pacific Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
  • TABLE 13 Latin America Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 14 Latin America Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 15 Latin America Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
  • TABLE 16 Middle East and Africa Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 17 Middle East and Africa Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 18 Middle East and Africa Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Angina Pectoris Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Angina Pectoris Treatment Market: Quality Assurance
  • FIG. 5 Global Angina Pectoris Treatment Market, By Drug Class, 2021
  • FIG. 6 Global Angina Pectoris Treatment Market, By Geography, 2021
  • FIG. 7 Global Angina Pectoris Treatment Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 8 U.S. Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 France Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 China Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 India Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
目次
Product Code: 136766-08-22

This report on global angina pectoris treatment market studies various drugs used for treatment of angina pectoris along with pipeline analysis of upcoming potential drugs. Angina is chest pain due to transient myocardial ischaemia, which usually occurs with physical activity or emotional stress, in the United States 10.2 million are estimated to experience angina with approximately 500,000 new cases occurring each year. Thus, drug pipeline of angina pectoris treatment market comprises potential drugs which are specific and fast in therapeutic action.

For the purpose of this study, the various drug classes studied include antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, short & long - acting nitroglycerines angiotensin-converting enzyme inhibitors and anti-ischemic agents. Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of USD Mn along with the respective CAGRs for the period 2022 to 2030, considering 2021 as the base year.

The pipeline analysis for angina pectoris treatment market comprises projected market sales of Phase III drugs estimated till 2030. The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Angina Pectoris Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Angina Pectoris Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Antiplatelet agents

Beta-adrenergic blocking agents

Calcium channel blockers

Short & Long - acting Nitroglycerines

Angiotensin-converting enzyme inhibitors

Anti-ischemic agents

Pipeline Analysis

Projected sales of Phase III Drugs estimated till 2030 (US$ Mn)

Dantonic/T89

RANCAD

Cilostazol

Bococizumab

Ticagrelor

Auto-CD34+ cells

Alirocumab

Tabular Representation of Phase II and I Drugs

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Angina Pectoris Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Angina Pectoris Treatment market?

Which is the largest regional market for Angina Pectoris Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Angina Pectoris Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Angina Pectoris Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Angina Pectoris Treatment Market
  • 2.2. Global Angina Pectoris Treatment Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Angina Pectoris Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Angina Pectoris Treatment Market Vendors
    • 2.6.2. Strategies Adopted by Angina Pectoris Treatment Market Vendors
    • 2.6.3. Key Industry Strategies

3. Angina Pectoris Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Angina Pectoris Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Antiplatelet agents
    • 4.3.2. Beta-adrenergic blocking agents
    • 4.3.3. Calcium channel blockers
    • 4.3.4. Short & Long - acting Nitroglycerines
    • 4.3.5. Angiotensin-converting enzyme inhibitors
    • 4.3.6. Anti-ischemic agents
    • 4.3.7. Pipeline Analysis
      • 4.3.7.1. Projected sales of Phase III Drugs estimated till 2030 (US$ Mn)
        • 4.3.7.1.1. Dantonic/T89
        • 4.3.7.1.2. RANCAD
        • 4.3.7.1.3. Cilostazol
        • 4.3.7.1.4. Bococizumab
        • 4.3.7.1.5. Ticagrelor
        • 4.3.7.1.6. Auto-CD34+ cells
        • 4.3.7.1.7. Alirocumab
      • 4.3.7.2. Tabular Representation of Phase II and I Drugs

5. North America Angina Pectoris Treatment Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 5.3.Angina Pectoris Treatment Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Angina Pectoris Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Angina Pectoris Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Angina Pectoris Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Angina Pectoris Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Angina Pectoris Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Angina Pectoris Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Angina Pectoris Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Angina Pectoris Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Abbott Laboratories Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Astra Zeneca plc
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. Bayer AG
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. Bristol-Myers Squibb Company
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. F. Hoffmann-La Roche Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Forest Laboratories Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Gilead Sciences, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. GlaxoSmithKline plc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Novartis AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Pfizer Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives
  • 10.11. Sanofi SA
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Initiatives